Business
Bionano Genomics Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
Conference Call and Webcast scheduled for today, Thursday, March 5 at 4:30 pm ET SAN DIEGO, March 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Conference Call and Webcast scheduled for today, Thursday, March 5 at 4:30 pm ET\nSAN DIEGO, March 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.\n Recent Business Highlights Announced updates to the Saphyr system designed to increase the speed of data collection, simplify sample preparation for solid tumors and animal tissue, and significantly improve total data yield per flow cell, allowing for a complete workflow for the in-depth analysis of complex, heterogeneous cancer samples. Also introduced a new reagent-rental sales model along with a competitively priced service model allowing researchers and labs access to the Saphyr system with minimum purchase commitments; Published a study in bioRxiv showing the Saphyr system’s 100% concordance with traditional cytogenetic methods in detecting somatic chromosomal abnormalities in the analysis of leukemia genomes. The study was conducted at the Radboud University Medical Center in the Netherlands; Presented a total of 34 (13 oral and 21 poster) presentations at the International Plant & Animal Genome (PAG) XXVIII Conference that discussed the use of Bionano’s systems to build the most complete and accurate genome assemblies and workflows to analyze variations of genome structure; Announced GeneDx’s adoption of the Saphyr system as part of its efforts to develop advanced tools to test for conditions caused by large structural variants based on Bionano’s optical mapping technology; Announced Mayo Clinic’s adoption of the Saphyr system in-house after determining that it could provide a deeper understanding of the genetic causes of neurodegenerative diseases and the routes to developing novel diagnostic assays and drugs to enable therapeutic interventions; Published four leukemia studies using Saphyr system in the special edition of the journal Blood prior to the start of the 2019 annual meeting of the American Society of Hematology (ASH) in conjunction with the launch of its DNA isolation kit for Bone Marrow Aspirates (BMA), the primary material collected in leukemia pa...